PDCD1 and neoplasm: Much of this research has centered on the use of gene editing to inactivate key immune checkpoint inhibitors such as programmed cell death protein-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4)—two proteins that normally inhibit the anti-tumor cytotoxic effect of endogenous and exogenous T cells84.